Cargando…

Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the North East India cohort of the A(1)chieve study

BACKGROUND: The A(1)chieve, a multicentric (28 countries), 24-week, non-interventional study evaluated the safety and effectiveness of insulin detemir, biphasic insulin aspart and insulin aspart in people with T2DM (n = 66,726) in routine clinical care across four continents. MATERIALS AND METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales: Sanyal, Debmalya, Basu, Debasis, Saikia, Mihir
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3872900/
https://www.ncbi.nlm.nih.gov/pubmed/24404492
http://dx.doi.org/10.4103/2230-8210.122102
_version_ 1782297035017289728
author Sanyal, Debmalya
Basu, Debasis
Saikia, Mihir
author_facet Sanyal, Debmalya
Basu, Debasis
Saikia, Mihir
author_sort Sanyal, Debmalya
collection PubMed
description BACKGROUND: The A(1)chieve, a multicentric (28 countries), 24-week, non-interventional study evaluated the safety and effectiveness of insulin detemir, biphasic insulin aspart and insulin aspart in people with T2DM (n = 66,726) in routine clinical care across four continents. MATERIALS AND METHODS: Data was collected at baseline, at 12 weeks and at 24 weeks. This short communication presents the results for patients enrolled from North East, India. RESULTS: A total of 730 patients were enrolled in the study. Four different insulin analogue regimens were used in the study. Patients had started on or were switched to biphasic insulin aspart (n = 518), insulin detemir (n = 88), insulin aspart (n = 74), basal insulin plus insulin aspart (n = 19) and other insulin combinations (n = 30). At baseline glycaemic control was poor for both insulin naïve (mean HbA(1)c: 9.5%) and insulin users (mean HbA(1)c: 9.2%) groups. After 24 weeks of treatment, both groups showed improvement in HbA(1)c (insulin naïve: −1.6%, insulin users: −1.5%). SADRs including major hypoglycaemic events or episodes did not occur in any of the study patients. CONCLUSION: Starting or switching to insulin analogues was associated with improvement in glycaemic control with a low rate of hypoglycaemia.
format Online
Article
Text
id pubmed-3872900
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-38729002014-01-08 Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the North East India cohort of the A(1)chieve study Sanyal, Debmalya Basu, Debasis Saikia, Mihir Indian J Endocrinol Metab Original Article BACKGROUND: The A(1)chieve, a multicentric (28 countries), 24-week, non-interventional study evaluated the safety and effectiveness of insulin detemir, biphasic insulin aspart and insulin aspart in people with T2DM (n = 66,726) in routine clinical care across four continents. MATERIALS AND METHODS: Data was collected at baseline, at 12 weeks and at 24 weeks. This short communication presents the results for patients enrolled from North East, India. RESULTS: A total of 730 patients were enrolled in the study. Four different insulin analogue regimens were used in the study. Patients had started on or were switched to biphasic insulin aspart (n = 518), insulin detemir (n = 88), insulin aspart (n = 74), basal insulin plus insulin aspart (n = 19) and other insulin combinations (n = 30). At baseline glycaemic control was poor for both insulin naïve (mean HbA(1)c: 9.5%) and insulin users (mean HbA(1)c: 9.2%) groups. After 24 weeks of treatment, both groups showed improvement in HbA(1)c (insulin naïve: −1.6%, insulin users: −1.5%). SADRs including major hypoglycaemic events or episodes did not occur in any of the study patients. CONCLUSION: Starting or switching to insulin analogues was associated with improvement in glycaemic control with a low rate of hypoglycaemia. Medknow Publications & Media Pvt Ltd 2013-11 /pmc/articles/PMC3872900/ /pubmed/24404492 http://dx.doi.org/10.4103/2230-8210.122102 Text en Copyright: © Indian Journal of Endocrinology and Metabolism http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Sanyal, Debmalya
Basu, Debasis
Saikia, Mihir
Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the North East India cohort of the A(1)chieve study
title Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the North East India cohort of the A(1)chieve study
title_full Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the North East India cohort of the A(1)chieve study
title_fullStr Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the North East India cohort of the A(1)chieve study
title_full_unstemmed Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the North East India cohort of the A(1)chieve study
title_short Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the North East India cohort of the A(1)chieve study
title_sort clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: results from the north east india cohort of the a(1)chieve study
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3872900/
https://www.ncbi.nlm.nih.gov/pubmed/24404492
http://dx.doi.org/10.4103/2230-8210.122102
work_keys_str_mv AT sanyaldebmalya clinicalexperiencewithinsulindetemirbiphasicinsulinaspartandinsulinaspartinpeoplewithtype2diabetesresultsfromthenortheastindiacohortofthea1chievestudy
AT basudebasis clinicalexperiencewithinsulindetemirbiphasicinsulinaspartandinsulinaspartinpeoplewithtype2diabetesresultsfromthenortheastindiacohortofthea1chievestudy
AT saikiamihir clinicalexperiencewithinsulindetemirbiphasicinsulinaspartandinsulinaspartinpeoplewithtype2diabetesresultsfromthenortheastindiacohortofthea1chievestudy